Nebido (Testosterone Undecanoate)

After intramuscular injection, testosterone undecanoate is slowly hydrolyzed to testosterone. The hormone binds to intracellular androgen receptors, forming a complex that moves into the cell nucleus and regulates gene transcription. This process supports the development and maintenance of male secondary sexual characteristics and metabolic functions.

The dosing regimen for Nebido is individualized by the prescribing healthcare professional based on the patient’s clinical condition, serum testosterone levels, and response to therapy. The prescriber determines the appropriate dose and injection interval.

Nebido is not indicated for use in pregnant or breastfeeding individuals. Testosterone therapy can affect fetal development and may be transferred to infants through breast milk, potentially causing hormonal disturbances. Women who are pregnant, planning pregnancy, or nursing should avoid exposure.

To request Nebido, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Nebido offers a long‑acting intramuscular formulation that requires fewer injections (typically every 10–14 weeks) compared with shorter‑acting testosterone esters that may need weekly or bi‑weekly dosing. This can improve patient adherence, but the choice of product depends on individual clinical needs, tolerability, and physician preference.

Nebido should be stored at 2‑8 °C in a refrigerator, protected from light. Do not freeze or shake the vials. If temporary temperature excursions occur, keep the product out of direct sunlight and return it to proper refrigeration as soon as possible.

Nebido is given by deep intramuscular injection, usually into the gluteal muscle. The injection is performed by a qualified healthcare professional using aseptic technique. The initial dose is followed by a maintenance schedule determined by the prescriber, often spaced several weeks apart.

Serious risks include cardiovascular events such as myocardial infarction or thromboembolism, hepatic dysfunction, and rapid progression of prostate disease. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if severe adverse reactions occur.

Nebido is contraindicated in individuals with known hypersensitivity to testosterone undecanoate, active prostate or breast cancer, severe untreated sleep apnea, uncontrolled heart failure, or those at high risk for thromboembolic disease. It should also be avoided in women, especially during pregnancy or lactation.